Why Corcept Therapeutics (CORT) Is Up 7.0% After First-in-Class Lifyorli FDA Approval And NCCN Nod

Corcept Therapeutics has received U.S. FDA approval for Lifyorli (relacorilant) in combination with nab-paclitaxel to treat adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of therapy including bevacizumab. This approval marks the first regulatory clearance for a selective glucocorticoid receptor antagonist and is based on data from the Phase 3 ROSELLA trial.

The FDA’s decision follows presentation of final overall survival data from the ROSELLA trial, which demonstrated that adding relacorilant to nab-paclitaxel improved both overall survival and progression-free survival in patients with platinum-resistant ovarian cancer. The trial did not require biomarker selection for enrollment.

Lifyorli is now listed as a preferred regimen in the National Comprehensive Cancer Network (NCCN) Guidelines for the treatment of platinum-resistant ovarian cancer. This inclusion supports clinical adoption and provides guidance to oncologists on recommended treatment options.

Lifyorli’s ovarian cancer approval meaningfully shifts the near term catalyst from “if” to “how fast,” as commercial uptake and payer access become central.

Simply Wall St

Corcept’s 2026 revenue guidance, issued prior to the FDA decision, projects net revenue between $900 million and $1 billion. This range now reflects a business with two approved products—Korlym for Cushing’s syndrome and Lifyorli for platinum-resistant ovarian cancer—as the company seeks to reduce dependence on its legacy product amid ongoing generic competition and patent litigation risks.

The approval introduces a new treatment option in a setting with limited alternatives and expands Corcept’s pipeline beyond endocrinology into oncology. Analysts note that successful commercialization will depend on rapid uptake, payer negotiations, and the ability to scale manufacturing and distribution infrastructure to match clinical demand.

While the approval reduces near-term uncertainty around Lifyorli’s market potential, investors continue to monitor risks related to Korlym’s market exclusivity, ongoing patent challenges, and the pace at which Lifyorli can offset declining revenues from the company’s legacy franchise.